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Introduction
Immunotherapy has become a viable treatment alternative for a number of advanced hematological malignancies and solid tumors Correspondence: Dr. Qiao Li e-mail: qiaoli@umich.edu 
CD19
+ B cells purified from 4T1 TDLNs. B cells were stained with anti-CD19 on the cell surface and intracellularly stained with anti-IL-10 or isotype control antibodies before and after A/E. (C, F) Detection of IL-10-producing cells in CD19 + B cells purified from WT healthy LNs. B cells were stained with anti-CD19 and anti-IL-10 antibodies before and after A/E, and at least 10 000 cells were analyzed by flow cytometry. Cells were initially gated on forward and side scatter to remove debris and calculated by quadrant dot plot analysis. Representative plots from single experiments out of three independent experiments are shown.
opposition. In previous studies, B-cell function in host immune responses was mainly focused on antigen presentation and antibody production. Recent B-cell studies have demonstrated that B cells can act either as effector cells [7, 8] or as regulatory cells [9] .
B cells are phenotypically and functionally heterogeneous [10, 11] . On one hand, in vivo primed and in vitro activated B cells have shown efficacy in adoptive immunotherapy of cancer [7, 8] , and the effector B cells can directly kill tumor cells [8] . On the other hand, resting B cells can promote the development or progression of cancer [12] [13] [14] [15] . One of the most significant findings in recent B-cell studies has been the identification of regulatory B cells or Breg cells [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] , which can suppress inflammatory responses in EAE, collagen-induced arthritis, and intestinal inflammation [16] [17] [18] . In the majority of these studies, the function of regulatory B cells is dependent on IL-10 production, but other mechanisms, including expression of TNF family death-inducing ligands, have been described [27] . It has been found that differentiated B cells expressing IL-10 can repress antitumor immunity [19, 20] .
We have previously published that about 40% of the tumordraining lymph node (TDLN) cells are CD19 + B cells [7, 8] . Using a murine 4T1 pulmonary metastatic model, we found that adoptive transfer of LPS/anti-CD40-activated 4T1 TDLN B cells significantly inhibited the development of spontaneous 4T1 pulmonary metastasis in tumor-bearing mice [8] . In the current study, we sought to examine the mechanisms involved in the B-cell-mediated tumor repression, and the role of IL-10-producing B cells in regulating the antitumor efficacy of B effector cells given in adoptive immunotherapy.
Results

IL-10 −/− B cells are more potent antitumor effector cells than WT B cells
Breg cells have been found to be immunosuppressive [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . To detect IL-10-producing cells in 4T1 TDLN B cells, we purified CD19 + B cells from WT and IL-10 −/− 4T1 TDLN cells, respectively.
WT 4T1 TDLNs were induced as previously described [8] , and the IL-10 −/− 4T1 TDLNs were induced by s.c. injection of 4T1 cells into the IL-10 −/− BALB/c mice. The CD19 + and CD19 + IL-10 + Bcell populations were assessed by flow cytometry. Among these freshly purified B cells, 2-3% of the WT B cells were CD19 + IL-10 + (Fig. 1A ), but these cells were not detectable in the IL-10 −/− B cells as expected (Fig. 1B) . After in vitro activation and expansion (A/E) with LPS plus anti-CD40, CD19 + IL-10 + cells in WT TDLN B cells increased to 11% (Fig. 1D) , while CD19 + IL-10 + cells in the IL-10 −/− B cells remained undetectable (Fig. 1E ). There were almost no IL-10-producing B cells in healthy LN (<1% before A/E, Fig. 1C ; <2% after A/E, Fig. 1F ).
To investigate the role of IL-10-producing B cells in adoptive immunotherapy of cancer, we compared the therapeutic efficacy of IL-10 −/− to WT TDLN B cells. Two weeks after 4T1 tumor cell injection into the mammary fat pad, tumor-bearing WT BALB/c mice were treated with activated WT or IL-10 −/− 4T1 TDLN B cells. Two weeks later, mice lungs were collected to enumerate pulmonary metastases. As shown in Fig. 2A , IL-2 alone or WT 4T1 TDLN B cells at a sub-optimal low dose (3 million/mouse) had a modest, but not significant reduction in pulmonary metastases compared with PBS-treated controls. However, adoptively transferred WT 4T1 TDLN B cells at a higher dose (15 million/mouse) significantly inhibited the metastasis of 4T1 tumor cells from the injection site (mammary fat pad) to the lung, which was consistent with our previous findings [8] . In comparison, the higher dose (15 In additional experiments, we found that IL-10 antibody injection alone did not demonstrate significant antitumor effect compared with no treatment controls (Fig. 3B) . Together, these studies verify that adoptive immunotherapy using effector TDLN B cells is more effective in the absence of IL-10.
Depletion of IL-10 significantly enhances systemic antitumor immunity
We purified PBMCs from the 4T1 tumor-bearing host subjected to WT TDLN B-cell adoptive immunotherapy with or without systemic IL-10 neutralization. T cells and B cells were purified from these PBMCs and were cultured as previously described [7, 8] . These cells were then analyzed for their lysis of the 4T1 cells. T cells ( We also purified splenic T-and B cells from all of the five experimental groups. Both splenic T- (Fig. 4C ) and splenic B cells (Fig. 4D ) harvested from the hosts subjected to 4T1 TDLN B-cell + IL-10 antibody treatment lysed 4T1 tumor cells significantly (p < 0.05) more efficiently than T-and B cells prepared from the hosts subjected to 4T1 TDLN B-cell alone, 4T1 TDLN B-cell + IgG1, IL-10 antibody only, or no treatment. Together, these data indicate that depletion of IL-10 in B-cell adoptive transfer significantly enhanced host systemic antitumor immunity.
Direct killing of 4T1 cells by 4T1 TDLN B cells involves the Fas/FasL pathway
In our observed direct killing of 4T1 tumor cells by B cells, either by effector 4T1 TDLN B cells used for adoptive transfer (Fig. 2B) , or by PBMCs and splenic B cells harvested from the host subjected to B-cell + IL-10 antibody treatment ( Fig. 4B and D) , there was no complement or other effector cells (e.g. NK cells, macrophages, or neutrophils) added in the assay. Therefore, such direct killing was distinct from the traditional complement-dependent cytotoxicity or antibody-dependent cell cytotoxicity.
B cells have been shown to express FasL that can bind to the target cells expressing Fas resulting in target cell death [11, 28, 29] . To examine whether 4T1 TDLN B-cell-mediated direct killing of 4T1 cells involved the Fas/FasL pathway, we used anti-FasL antibody to block FasL during the LDH release assay. When added in culture, anti-FasL antibody significantly and dose-dependently decreased the killing efficacy of TDLN B cells on 4T1 tumor cells at the E:T ratios of 10:1 and 30:1 (Fig 5A, Expt. 1, anti-FasL = 10 μg/mL; Expt. 2, anti-FasL = 30 μg/mL).
We used TDLN B cells isolated from IL-10 −/− knockout mice and compared their FasL expression with WT TDLN B cells. As shown in Fig. 5B , approximately 5% of the purified and anti-CD40/LPS A/E WT TDLN B cells expressed FasL. These are the effector cells we used for adoptive transfer, in vitro killing assays, and anti-FasL blockade throughout the study. As also observed in 
Adoptively transferred B cells traffic to the tumor and lung in vivo
To address homing of the transferred B cells we prelabeled the purified and activated/expanded TDLN B cells with 10 μM Cell Tracker TM Orange CMTMR (Fig. 6A) . After adoptive transfer, spleens, TDLNs, lungs, and primary tumors were harvested at specified time points to detect the labeled live B cells in these tissues. As shown in (Table 1 ). These data suggest that transferred B cells did not preferentially home to the tumor sites, but that they were more prone to entering sites of tumor than were endogenous B cells. This suggests that the ex vivo activation of TDLN B cells enhanced their trafficking to tumor sites which may have enhanced their ability to prevent lung metastasis. In the above experiments, we also used tumor-free mice as recipients of labeled TDLN B cells and found very few transferred B cells in the lung (Fig. 6C ) or in the spleen and LN of the healthy mice (data not shown). These results imply that localization and/or survival of the adoptively transferred TDLN B cells is critically dependent on interaction with the 4T1 tumor cells in vivo.
Discussion
Breg cells, a subset of B cells analogous to regulatory T (Treg) cells, have been identified in experimental models of autoimmunity, infections, and cancer [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] 30] . Breg suppression appears to be directly mediated by the secretion of IL-10 and by B-cell interaction with pathogenic T cells to suppress immune responses [9]. IL-10-producing B cells play an important role in controlling encephalomyelitis, arthritis, and other inflammatory reactions [16-18, 23, 31] . Breg cells have demonstrated a negative effect in antitumor immunity, and promote the development of Treg cells. However, previous studies in our laboratory have shown that B cells isolated from tumor draining lymph nodes can induce anti-tumor T-cell responses and tumor regression [7, 8] . We previously demonstrated that the adoptive transfer of purified effector B cells was highly potent in mediating tumor regression of established subcutaneous tumors in hosts that had been preconditioned with total body irradiation (500 cGy) that eliminated host T cells [7] . This clearly indicated that transferred B cells can act independently of T cells in causing tumor destruction in vivo. In addition, adoptively transferred effector B cells can also induce host T-cell anti-tumor activity [8] . We have previously reported that in the 3-day established pulmonary metastatic model the intravenous administration of neutralizing IL-10 mAb does not impact on the number of pulmonary metastases compared to untreated mice [32] . This indicates that endogenous host T-and B cells are not sufficient to mediate tumor regression when IL-10 is neutralized. In that same study, we found that adoptive transfer of activated T cells mediated tumor regression that was enhanced by IL-10 neutralization. This latter study plus our current data indicate that the ex vivo activation and adoptive transfer of either T or B effector cells is necessary and sufficient to see an effect of IL-10 neutralization.
To determine the mechanism by which the transferred B cells were controlling 4T1 tumor metastases, we studied the potential role of FasL expression by B cells in our model [11] . The Fas/FasL axis has shown a key role in regulating T cells during autoimmunity, infection, and cancer [11] . LPS-activated splenic B cells and B cells from healthy lymphoid tissues express FasL [28, 29, 33, 34] . Klinker We have described that in vivo primed and in vitro activated effector B cells can mediate tumor regression after adoptive transfer [7, 8] . In an earlier report, Harada et al. [36] demonstrated that LPS-activated B cells bound to anti-CD3 mAb enhanced the antitumor T-cell response. Unique to our model is the source of our in vivo primed B cells that are from tumor-draining LNs. Importantly, these LNs harbor tumor-specific T-and B cells secondary to DC sensitization. Messina et al. [37] reported that unique lymph node-like structures found in metastatic human melanomas correlated with improved overall survival. These structures contained an abundance of follicles with B-and T cells, suggesting the presence of an immune response associated with improved survival. We postulate that both a T-and B-cell response to tumor is important in developing effective immunotherapies.
It has been reported that T cells or TDLN cells can directly migrate to tumor and LN, and function in metastasis [38, 39] 
Materials and methods
Mice
Female WT and IL-10 KO (Il10 tm1Cgn , IL-10 −/− ) BALB/c mice were purchased from the Jackson Laboratories (Bar Harbor, ME). IL-10 KO mice on BALB/c background are homozygous for a mutation in the IL-10 gene achieved by vectors designed to replace codons 5-55 of exon 1 with a 24 bp linker (providing a termination codon) and a neo expression cassette, to introduce a termination codon into exon 3. Mice were maintained in a pathogen-free environment and used at age 7 weeks or older. Principles of laboratory animal care (NIH publication No. 85-23, revised 1985) were followed. The animal protocols were approved by the University of Michigan Unit of Laboratory of Animal Medicine.
Murine tumor cells
The 4T1 cell line is a mammary carcinoma syngeneic to BALB/c mice (kindly provided by Dr. M. Sabel, University of Michigan). Inoculating 4T1 cells into the mammary fat pad induces the development of spontaneous pulmonary metastases. Renca is a kidney cancer cell line and TSA is a highly aggressive mammary adenocarcinoma, and these cell lines are all syngeneic to BALB/c mice and used as tumor antigen-specific controls. Renca and TSA were purchased from American type culture collection (Rockville, MD). All cell lines were maintained in vitro in complete medium (CM).
Tumor draining lymph nodes
To induce TDLNs, 1 × 10 6 4T1 tumor cells in 0.1 mL PBS were injected s.c. into the lower flanks of WT or IL-10 −/− syngeneic mice. Nine days after 4T1 cell inoculation, the draining inguinal lymph nodes were collected and processed using mechanical dissociation, filtered through nylon mesh and washed in HBSS. Multiple inguinal TDLNs were pooled from each group of mice for cell preparation.
T-cell and B-cell activation and expansion
CD19
+ B cells were purified from the TDLN cells, healthy LN, PBMCs, or splenocytes using anti-CD19-coupled MACS beads (MiltenyiBiotec, Auburn, CA). CD3 + T cells were purified from PBMCs or splenocytes using anti-CD3-coupled MACS beads. B cells were activated with LPS (Sigma-Aldrich, Atlanta, GA) plus anti-CD40 (FGK45) mAb ascites in CM at 37°C with 5% CO 2 for 3-4 days [7, 8] . FGK45 hybridoma cells (American type culture collection) were cultured and ascites were generated by the Hybridoma Core at the University of Michigan. T cells were activated with immobilized anti-CD3 and anti-CD28 mAbs in CM containing IL-2 (Prometheus Laboratories, San Diego, CA) [7, 8] .
Flow cytometry
Cell expression of CD19, Fas, FasL, CD25, and IL-10 were analyzed. All conjugated antibodies (FITC or allophycocyanin anti-CD19, PE anti-Fas, PE anti-CD25, PE anti-IL-10, and PE antiFasL) and isotype controls were purchased from BD Biosciences (San Jose, CA). For intracellular IL-10 expression, 1 million TDLN B cells were incubated with 2 μL/mL Leukocyte Activation Cocktail and 0.67 μL/mL Golgistop (BD Biosciences) in 6-well plate for 4-6 h at 37°C with 5% CO 2, and then stained with anti-IL-10. For FasL expression, purified, and A/E TDLN B cells were cultured with or without 4T1 at 37°C with 5% CO 2 overnight. After being fixed and permeabilized with Fixation/Perm Buffer (eBioscience, San Diego, CA), the cells were stained with anti-FasL. Isotype control staining was used to define the gates for positive and negative cells. BD FACSDiva software (version 7.0) was used for all flow cytometry analysis.
Adoptive TDLN B-cell therapy
Healthy BALB/c mice were inoculated with 5 × 10 4 4T1 cells into the mammary fat pad. Fourteen days after tumor inoculation, the tumor-bearing mice were treated with tail vein injection of activated WT or IL-10 −/− 4T1 TDLN B cells. Commencing on the day of the effector B-cell transfer, i.p. injections of IL-2 (40 000 IU) were administered in 0.5 mL of PBS and continued twice daily for eight doses. Two weeks after B-cell transfer, all mice were sacrificed and lungs were harvested for enumeration of spontaneous pulmonary metastatic nodules. For IL-10 neutralization, the 4T1 tumor-bearing mice were prepared as above and starting on the same day as B-cell transfer mice were injected i.p. with IL-10 antibody (200 μg/mouse) or isotype control antibody (Bio X Cell, West Lebanon, NH) daily for 4 days. Two weeks after B-cell transfer, mice were sacrificed and pulmonary metastatic nodules were counted. At the same time, peripheral blood and spleens were collected for purification of PBMCs and splenic T-and B cells as described above.
Tracking adoptively transferred B cells in vivo
Activated TDLN B cells were labeled with 10 μM Cell Tracker TM Orange CMTMR (5-(and-6)-(((4-chloromethyl) benzoyl) amino) tetramethyl rhodamine) (Life Technology, Grand Island, NY) at 37°C for 45 min in the dark. The labeled B cells were visualized by Nikon eclipse-TE 300 and Q-capture Pro 7 software. At day 1/5/9/14 after adoptive transfer, the tumor-bearing mice and healthy mice were sacrificed and their spleens, TDLNs, lungs, and tumors (healthy mice had no tumor) were collected and the labeled B cells of all B cells in these tissues were detected by flow cytometry.
LDH cytotoxicity assay
Cell cytotoxicity was assessed by measuring the release of cytoplasmic LDH using CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI). Effector B cells were generated from WT or IL-10 −/− TDLN B cells using LPS/anti-CD40 as described above.
Target 4T1 cells were plated in triplicate in a 96-well U-bottom tissue culture plate (5000 cells/well) and coincubated with TDLN B cells at effector to target cell ratios of 1:1, 3:1, 10:1, and 30:1. After 12 h of incubation, cells were centrifuged and 50 μL supernatant from each well was transferred to a fresh 96-well plate, 50 μL of the substrate mix was added and incubated at room temperature in the dark for 15-30 min. Before LDH measurement, 50 μL of stop solution was added to each well. Maximal release of LDH was performed by incubating the target cells with Lysis Solution (Promega). Target cells without effector cells were used as spontaneous release control. Absorbance was measured at 490 nm using a 96-well plate reader. For assays of PBMCs or spleen cell cytotoxicity, effector T-or B cells were generated by anti-CD3/anti-CD28 plus IL-2 or LPS/anti-CD40 activation, respectively. The T-cell killing assay was incubated for 4-6 h instead of the 12 h used for B-cell-mediated cytotoxicity. For blocking of B-cell cytotoxicity the cultures were performed as described above in the presence or absence of 10 or 30 μg/mL anti-FasL antibody (Biolegend, San Diego, CA).
Statistical analysis
GraphPad Prism 6.0 software was used for statistical analysis. The significance of differences in numbers of metastatic nodules and cell lysis was determined using Student's t-test. p < 0.05 was considered statistically significant between the experimental groups.
